Genetics: Lack of association between slco1b1 polymorphisms and clinical myalgia following rosuvastatin therapy

American Heart Journal

Volumn 165, Issue 6, 2013, Pages 1008-1014

  Danik, Jacqueline S ^a,e,f   Chasman, Daniel I ^a,e,f   MacFadyen, Jean G ^a,e,f   Nyberg, Fredrik ^b,c,e,f   Barratt, Bryan J ^d,e,f   Ridker, Paul M ^a,e,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e Brigham and Women's Hospital ^*

^f not available   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANIC ANION TRANSPORTER 2; PLACEBO; ROSUVASTATIN; DNA; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORGANIC ANION TRANSPORTER; PYRIMIDINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; SULFONAMIDE;

ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MULTICENTER STUDY; MUSCLE DISEASE; PRIMARY PREVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ALLELES; CARDIOVASCULAR DISEASES; DNA; DOUBLE-BLIND METHOD; FLUOROBENZENES; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; PRIMARY PREVENTION; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES;

MLCS; MLOWN;

EID: 84880051381     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.01.025     Document Type: Article

References (38)

1. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy-A genomewide study. N Engl J Med 2008;359: 789-99.
2. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.
3. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-9.
4. Pasanen MK, Fredrikson H, Neuvonen PJ, et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33.
5. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATPC, SLCO1B1). Pharmacogenetics 2004;14:429-40.
6. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41.
7. Choi JH, Lee MG, Cho JY, et al. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 2008;83:251-7.
8. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
9. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-61.
10. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation 2003;108:2292-7.
11. MedDRA Maintenance and Support Services Organization. Introductory Guide, MedDRA version 10.1: International Federation of Pharmaceutical Manufacturers and Associations; 2007 Sep.
12. Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012; 5:257-64.
13. www.nbci.nlm.nih.gov/snp. Accessed June 12, 2012.
14. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.
15. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9.
16. Brown C, Windass A, Bleasby K, et al. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atheroscler Suppl 2001;2:90. Abstract P174.
17. Ho RH, Wang Y, Leake BF, et al. Multiple OATP transporters mediate the cellular uptake of rosuvastatin. Clin Pharmacol Ther 2005;77: P64-P.
18. Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 2005;15:513-22.
19. Konig J, Seithel A, Gradhand U, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372:432-43.
20. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822-35.
21. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001;297:861-7.
22. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001;276:35669-75.
23. Iwai M, Suzuki H, Ieiri I, et al. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 2004;14:749-57.
24. Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002;302:804-13.
25. Romaine SP, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 2010;10:1-11.
26. Morimoto K, Oishi T, Ueda S, et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 2004;19:453-5.
27. Martin NG, Li KW, Murray H, et al. The effects of a SNP in SLCO1B1 on the pharmacodynamics of pravastatin. Br J Clin Pharmacol 2011.
28. Takane H, Miyata M, Burioka N, et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006;51:822-6.
29. Niemi M, Neuvonen PJ, Hofmann U, et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 2005;15: 303-9.
30. Gerloff T, Schaefer M, Mwinyi J, et al. Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch Pharmacol 2006;373:45-50.
31. Akao H, Polisecki E, Kajinami K, et al. Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly. Atherosclerosis 2012;220: 413-7.
32. Tachibana-Iimori R, Tabara Y, Kusuhara H, et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 2004; 19:375-80.
33. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B-32B.
34. Hatanaka T. Clinical pharmacokinetics of pravastatin: Mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000;39: 397-412.
35. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991;80:830-4.
36. Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106:1024-8.
37. Backes JM, Howard PA, Ruisinger JF, et al. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 2009;43:2012-20.
38. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010;211:28-9.